contd. C1

(New) The method of claim

(New) The method of claim 16, wherein the compound has the formula: wherein R₁ is selected from the group consisting of hydrogen, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂.

4

(New) The method of claim $\frac{48}{1}$, wherein R_1 is hydrogen or fluoro; and R_3 is hydroxy or -OCONH₂.

30.

(New) The method of claim 4%, wherein R_1 is hydrogen and R_3 is -OCONH₂.

5¥.

(New) The method of claim 45, wherein the composition is administered orally.

5/2.

(New) The method of claim 46, wherein the unit dosage form of the composition comprises about 0.1 mg/kg to about 1 g/kg of said compound.

52

(New) A method for preventing or limiting tissue damage resulting from an ischemic event comprising administering to the patient, an effective amount of a compound having the formula:

16421

$$R_1$$
 R_2
 R_3
 R_3
 R_1
 R_3
 R_3
 R_3

wherein R₁, R₇ and R₈ are independently selected from the group consisting of hydrogen, halo, alkyl, haloalkyl and hydroxy; and R₃ is hydroxy or -OCONH₂.

9

(New) The method of claim 5%, wherein R_1 is selected from the group consisting of halo, haloalkyl and hydroxy.

0

Serial Number: 10/023,059 Filing Date: December 17, 2001

Title: FELBAMATE DERIVED COMPOUNDS

Page 3 Dkt: 1036.031US3

contab.

(New) The method of claim 53, wherein the compound has the formula:

wherein R_1 is selected from the group consisting of hydrogen, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂.

11 /0

56. (New) The method of claim 55, wherein R_1 is hydrogen or fluoro; and R_3 is hydroxy or OCON H_2 .

(New) The method of claim 56, wherein R₁ is hydrogen; and R₃ is -OCONH₂.

58. (New) The method of claim 53, wherein the tissue damage is caused by cerebral ischemia.

59. (New) The method of claim 52, wherein the tissue damage is caused by myocardial ischemia.

(New) The method of claim 58, wherein the compound is administered orally.

(New) The method of claim 5%, wherein the compound is administered parenterally.

(New) The method of claim 61, wherein the compound is in a composition comprising a pharmaceutically acceptable carrier.

 \mathcal{C}